Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

Examining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell disease.

Haywood C Jr, Beach MC, Bediako S, Carroll CP, Lattimer L, Jarrett D, Lanzkron S.

Am J Hematol. 2011 Jan;86(1):85-7. doi: 10.1002/ajh.21883.

2.

Hydroxyurea for the treatment of sickle cell disease.

Segal JB, Strouse JJ, Beach MC, Haywood C, Witkop C, Park H, Wilson RF, Bass EB, Lanzkron S.

Evid Rep Technol Assess (Full Rep). 2008 Mar;(165):1-95. Review.

3.

Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, Ballas SK, McMahon RP, Castro O, Orringer EP.

Medicine (Baltimore). 1996 Nov;75(6):300-26.

4.

Parental and other factors associated with hydroxyurea use for pediatric sickle cell disease.

Oyeku SO, Driscoll MC, Cohen HW, Trachtman R, Pashankar F, Mullen C, Giardina PJ, Velazco N, Racine AD, Green NS.

Pediatr Blood Cancer. 2013 Apr;60(4):653-8. doi: 10.1002/pbc.24381. Epub 2012 Nov 5.

5.

On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease.

el-Hazmi MA, al-Momen A, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F, Warsy AS.

Acta Haematol. 1995;94(3):128-34.

PMID:
7502628
6.

Hydroxyurea therapy for sickle cell disease in community-based practices: a survey of Florida and North Carolina hematologists/oncologists.

Zumberg MS, Reddy S, Boyette RL, Schwartz RJ, Konrad TR, Lottenberg R.

Am J Hematol. 2005 Jun;79(2):107-13.

7.

Hydroxyurea therapy in sickle cell anemia patients aids to maintain oral fungal colonization balance.

Salvia AC, Figueiredo MS, Braga JA, Pereira DF, Brighenti FL, Koga-Ito CY.

J Oral Pathol Med. 2013 Aug;42(7):570-5. doi: 10.1111/jop.12029. Epub 2012 Dec 26.

PMID:
23278631
8.

Do difficulties in swallowing medication impede the use of hydroxyurea in children?

Bekele E, Thornburg CD, Brandow AM, Sharma M, Smaldone AM, Jin Z, Green NS.

Pediatr Blood Cancer. 2014 Sep;61(9):1536-9. doi: 10.1002/pbc.25073. Epub 2014 Apr 17.

9.

A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle-cell disease.

Creary SE, Gladwin MT, Byrne M, Hildesheim M, Krishnamurti L.

Pediatr Blood Cancer. 2014 Jun;61(6):1068-73. doi: 10.1002/pbc.24931. Epub 2014 Jan 16.

PMID:
24436121
10.

Adherence to hydroxyurea, health-related quality of life domains, and patients' perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults.

Badawy SM, Thompson AA, Lai JS, Penedo FJ, Rychlik K, Liem RI.

Health Qual Life Outcomes. 2017 Jul 5;15(1):136. doi: 10.1186/s12955-017-0713-x.

11.

Higher nocturnal and awake oxygen saturations in children with sickle cell disease receiving hydroxyurea therapy.

Narang I, Kadmon G, Lai D, Dhanju S, Kirby-Allen M, Odame I, Amin R, Lu Z, Al-Saleh S.

Ann Am Thorac Soc. 2015 Jul;12(7):1044-9. doi: 10.1513/AnnalsATS.201410-473OC.

PMID:
25970812
12.

Use of hydroxyurea in children with sickle cell disease: what comes next?

Ohene-Frempong K, Smith-Whitley K.

Semin Hematol. 1997 Jul;34(3 Suppl 3):30-41. Review.

PMID:
9317199
13.

Hydroxyurea in children: present and future.

Vichinsky EP.

Semin Hematol. 1997 Jul;34(3 Suppl 3):22-9. Review.

PMID:
9317198
14.

Monitoring toxicity, impact, and adherence of hydroxyurea in children with sickle cell disease.

Brandow AM, Panepinto JA.

Am J Hematol. 2011 Sep;86(9):804-6. doi: 10.1002/ajh.22101. Epub 2011 Aug 3. No abstract available.

15.

Provider barriers to hydroxyurea use in adults with sickle cell disease: a survey of the Sickle Cell Disease Adult Provider Network.

Lanzkron S, Haywood C Jr, Hassell KL, Rand C.

J Natl Med Assoc. 2008 Aug;100(8):968-73.

PMID:
18717150
17.

Emerging science of hydroxyurea therapy for pediatric sickle cell disease.

Green NS, Barral S.

Pediatr Res. 2014 Jan;75(1-2):196-204. doi: 10.1038/pr.2013.227. Epub 2013 Nov 19. Review.

18.

Clinical complications in severe pediatric sickle cell disease and the impact of hydroxyurea.

Tripathi A, Jerrell JM, Stallworth JR.

Pediatr Blood Cancer. 2011 Jan;56(1):90-4. doi: 10.1002/pbc.22822. Epub 2010 Oct 4.

PMID:
20922765
19.

Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia.

Koren A, Segal-Kupershmit D, Zalman L, Levin C, Abu Hana M, Palmor H, Luder A, Attias D.

Pediatr Hematol Oncol. 1999 May-Jun;16(3):221-32.

PMID:
10326220
20.

Hydroxyurea therapy for children with sickle cell disease: describing how caregivers make this decision.

Creary S, Zickmund S, Ross D, Krishnamurti L, Bogen DL.

BMC Res Notes. 2015 Aug 25;8:372. doi: 10.1186/s13104-015-1344-0.

Supplemental Content

Support Center